Concert Pharmaceuticals, Inc. (CNCE) Stock Analysis
DELISTED 2023
What happened to Concert Pharmaceuticals, Inc. (CNCE) stock?
Concert Pharmaceuticals, Inc. (CNCE) no longer trades on public markets. It was delisted in March 2023. The figures below are historical and are not a current quote.
- Status:
- Delisted — no longer trades
- Delisting date:
- March 2023
- Last recorded price (historical):
- $8.37 (last quote on record before the March 2023 delisting; historical, not a current quote)
For informational purposes only. Not financial advice. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Concert Pharmaceuticals, Inc. (CNCE). Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative small molecule drugs for autoimmune diseases. Its lead candidate, CTP-543, is currently in Phase III trials targeting alopecia areata.
Last analyzed: May 10, 2026Concert Pharmaceuticals, Inc. (CNCE) Healthcare & Pipeline Overview
More about this archive record
Can I still buy CNCE shares?
No. CNCE stopped trading on public markets in March 2023, so the shares are not available through a broker. Anything you see quoted for CNCE elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before CNCE stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Concert Pharmaceuticals, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.